BNC 210
Alternative Names: BNC-210; IW 2143Latest Information Update: 22 Apr 2025
At a glance
- Originator Bionomics
- Developer Bionomics; EmpathBio
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Anxiety disorders
- Phase II Agitation; Post-traumatic stress disorders
- No development reported Depressive disorders
Most Recent Events
- 15 Apr 2025 Neuphoria Therapeutics plans to initiate a phase IIb trial in Post-traumatic stress disorder in the fourth quarter of 2025
- 28 Mar 2025 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders(Combination therapy) in Australia (PO)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders(Combination therapy) in USA (PO)